Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Activartis’ Cancer Immunotherapy Receives Orphan Drug Designation from FDA

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
The ODD applies specifically to the use of AV0113 for the treatment of malignant glioma, a very aggressive type of brain cancer.

The European drug agency EMA already granted ODD at the end of last year.

In principle, Activartis’ AV0113 Cancer Immunotherapy may be used to fight any type of cancer. The individualized therapeutic technology is based on a patented procedure in which a cancer patient’s immune system is primed to fight the tumor and eventually control its growth. This concept is based on the use of Dendritic Cells, the key regulatory elements of the immune system, that are the same as the tumor tissue derived from the patient.

Active cancer immunotherapy based on Dendritic Cells

AV0113 activates the patient’s immune system, with tumor cells being identified on the basis of their antigens and destroyed. The therapy makes use of elements and mechanisms of the immune system and gets to work where these fail. As tumor cells are the body’s own tissue, the immune system does not normally identify them as dangerous. Activartis’ AV0113 Cancer Immunotherapy “tricks” Dendritic Cells and, consequently, a cancer patient’s immune system, into doing the right thing, i.e. to perceive the tumor as a threat and to trigger adequate defense mechanisms.

The Dendritic Cells are charged with tumor-derived antigens, determinants that distinguish a tumor cell from a normal cell. These antigens are processed by the Dendritic Cell and shuttled to the cell surface in order to present them to T-cells. This, however, is not sufficient to prime an immune response against the tumor antigens. The “trick” referred to above is contacting Dendritic Cells with a microbial danger signal. Certain molecules that are present in microorganisms but not in higher organisms signal to the Dendritic Cell the presence of a microbial invasion in its surroundings and hence danger to the organism.

As tumor cells originate from a cancer patient’s normal cells, they do not provide danger molecules which are recognized by the Dendritic Cell. The critical and unique part of Activartis’ AV0113 technology is exposing tumor antigen-charged Dendritic Cells to one of these danger molecules: lipopolysaccharides, the bacterial endotoxins. This causes the Dendritic Cell to assume a potently immune stimulatory and pro-inflammatory mode of action. Upon returning these Dendritic Cells to the patient, they activate tumor-specific T-cells, most importantly the so-called cytotoxic T-cells, which become able to recognize and destroy tumor cells.

Early results of the Activartis AV0113 trial reveal a promising trend.

At the beginning of 2013, Activartis completed recruitment of 78 brain cancer patients to a multi-centre, randomized, phase II clinical trial. This randomized study aims to deliver safety and efficacy data for the first time. Preliminary results presented at the AACR Annual Meeting (April 6-10, 2013, Washington) revealed a very promising trend suggesting a survival benefit of patients in the AV0113 treatment group compared to the randomized control group.

Confirmation of that trend is expected by the end of 2013. If the trend currently observed is confirmed, AV0113 is bound to become part of the standard therapy for GBM.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Early Results of Activartis AV0113 Cancer Immunotherapy in Glioblastoma Trial Reveal Promising Trend
Glioblastoma multiforme (GBM) is the most severe form of brain cancer and progresses rapidly.
Thursday, April 11, 2013
Activartis Develops Dendritic Cell-Based Therapeutic Cancer Vaccine in Phase II
Results from multi-centre phase II clinical study expected in 2012.
Monday, October 31, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
NIH Launches Early-Stage Yellow Fever Vaccine Trial
Researchers at NIH have begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
JPK NanoWizard® Applied to a Wide Range of Research
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Protein Boosts Rice Yield by 54%
Over-expression of a natural protein in rice plants led to a 54% increase in crop yield and 40% increase in nitrogen-use efficiency.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!